GLIS2

Across TCGA pan-cancer cohorts, GLIS2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of GLIS2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where GLIS2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GLIS2 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where GLIS2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GLIS2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	−0.561	<.001	5	view →
LSCC	All	All	−0.583	.002	4	view →
CCRCC	Male	All	+0.517	.005	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

GLIS2–LUAD

Open the LUAD breakdown →